

# Paul Dowling

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6841088/publications.pdf>

Version: 2024-02-01

54  
papers

1,279  
citations

304743

22  
h-index

395702

33  
g-index

55  
all docs

55  
docs citations

55  
times ranked

1727  
citing authors

#	ARTICLE	IF	CITATIONS
1	The development of cisplatin resistance in neuroblastoma is accompanied by epithelial to mesenchymal transition in vitro. <i>Cancer Letters</i> , 2015, 364, 142-155.	7.2	79
2	Targeting Proteotoxic Stress in Cancer: A Review of the Role that Protein Quality Control Pathways Play in Oncogenesis. <i>Cancers</i> , 2019, 11, 66.	3.7	73
3	Drastic reduction of sarcalumenin in Dp427 (dystrophin of 427 kDa)-deficient fibres indicates that abnormal calcium handling plays a key role in muscular dystrophy. <i>Biochemical Journal</i> , 2004, 379, 479-488.	3.7	67
4	Mitochondrial Dysfunction Reveals the Role of mRNA Poly(A) Tail Regulation in Oculopharyngeal Muscular Dystrophy Pathogenesis. <i>PLoS Genetics</i> , 2015, 11, e1005092.	3.5	64
5	Label-free mass spectrometric analysis of the mdx <sup>4cv</sup> diaphragm identifies the matricellular protein periostin as a potential factor involved in dystrophinopathy-related fibrosis. <i>Proteomics</i> , 2015, 15, 2318-2331.	2.2	51
6	Targeting histone deacetylase 3 (HDAC3) in the bone marrow microenvironment inhibits multiple myeloma proliferation by modulating exosomes and IL-6 trans-signaling. <i>Leukemia</i> , 2020, 34, 196-209.	7.2	48
7	Proteomic profiling of cardiomyopathic tissue from the aged mdx model of Duchenne muscular dystrophy reveals a drastic decrease in laminin, nidogen and annexin. <i>Proteomics</i> , 2013, 13, 2312-2323.	2.2	46
8	Proteomic analysis of dystrophin deficiency and associated changes in the aged mdx-4cv heart model of dystrophinopathy-related cardiomyopathy. <i>Journal of Proteomics</i> , 2016, 145, 24-36.	2.4	46
9	Proteomic profiling of muscle fibre type shifting in neuromuscular diseases. <i>Expert Review of Proteomics</i> , 2016, 13, 783-799.	3.0	43
10	Carbon Catabolite Repression in Filamentous Fungi Is Regulated by Phosphorylation of the Transcription Factor CreA. <i>MBio</i> , 2021, 12, .	4.1	41
11	Pathoproteomic profiling of the skeletal muscle matrisome in dystrophinopathy associated myofibrosis. <i>Proteomics</i> , 2016, 16, 345-366.	2.2	40
12	Comparative Skeletal Muscle Proteomics Using Two-Dimensional Gel Electrophoresis. <i>Proteomes</i> , 2016, 4, 27.	3.5	35
13	Proteomic profiling of mdx-4cv serum reveals highly elevated levels of the inflammation-induced plasma marker haptoglobin in muscular dystrophy. <i>International Journal of Molecular Medicine</i> , 2017, 39, 1357-1370.	4.0	34
14	Comparative analysis of Dp427-deficient mdx tissues shows that the milder dystrophic phenotype of extraocular and toe muscle fibres is associated with a persistent expression of Î²-dystroglycan. <i>European Journal of Cell Biology</i> , 2003, 82, 222-230.	3.6	33
15	Identification of proteins found to be significantly altered when comparing the serum proteome from Multiple Myeloma patients with varying degrees of bone disease. <i>BMC Genomics</i> , 2014, 15, 904.	2.8	33
16	Aminopeptidase Expression in Multiple Myeloma Associates with Disease Progression and Sensitivity to Melflufen. <i>Cancers</i> , 2021, 13, 1527.	3.7	29
17	Elevated levels of 14-3-3 proteins, serotonin, gamma enolase and pyruvate kinase identified in clinical samples from patients diagnosed with colorectal cancer. <i>Clinica Chimica Acta</i> , 2015, 441, 133-141.	1.1	28
18	The Dystrophin Node as Integrator of Cytoskeletal Organization, Lateral Force Transmission, Fiber Stability and Cellular Signaling in Skeletal Muscle. <i>Proteomes</i> , 2021, 9, 9.	3.5	27

#	ARTICLE	IF	CITATIONS
19	Proteomic analysis of bronchoalveolar lavage fluid (BALF) from lung cancer patients using label-free mass spectrometry. <i>BBA Clinical</i> , 2017, 7, 97-104.	4.1	25
20	Characterization of Contractile Proteins from Skeletal Muscle Using Gel-Based Top-Down Proteomics. <i>Proteomes</i> , 2019, 7, 25.	3.5	25
21	Mass Spectrometry-Based Identification of Muscle-Associated and Muscle-Derived Proteomic Biomarkers of Dystrophinopathies. <i>Journal of Neuromuscular Diseases</i> , 2014, 1, 15-40.	2.6	24
22	A novel inhibitory anti-invasive MAb isolated using phenotypic screening highlights AnxA6 as a functionally relevant target protein in pancreatic cancer. <i>British Journal of Cancer</i> , 2017, 117, 1326-1335.	6.4	24
23	Emerging proteomic biomarkers of X-linked muscular dystrophy. <i>Expert Review of Molecular Diagnostics</i> , 2019, 19, 739-755.	3.1	24
24	Current Methods of Post-Translational Modification Analysis and Their Applications in Blood Cancers. <i>Cancers</i> , 2021, 13, 1930.	3.7	24
25	Proteome-wide Changes in the mdx-4cv Spleen due to Pathophysiological Cross Talk with Dystrophin-Deficient Skeletal Muscle. <i>IScience</i> , 2020, 23, 101500.	4.1	21
26	Protocol for the Bottom-Up Proteomic Analysis of Mouse Spleen. <i>STAR Protocols</i> , 2020, 1, 100196.	1.2	20
27	Multi-parametric single cell evaluation defines distinct drug responses in healthy hematologic cells that are retained in corresponding malignant cell types. <i>Haematologica</i> , 2020, 105, 1527-1538.	3.5	19
28	Proteomic and cell biological profiling of the renal phenotype of the mdx-4cv mouse model of Duchenne muscular dystrophy. <i>European Journal of Cell Biology</i> , 2020, 99, 151059.	3.6	19
29	Transferrin-bound proteins as potential biomarkers for advanced breast cancer patients. <i>BBA Clinical</i> , 2014, 2, 24-30.	4.1	18
30	Metabolomic and proteomic analysis of breast cancer patient samples suggests that glutamate and 12-HETE in combination with CA15-3 may be useful biomarkers reflecting tumour burden. <i>Metabolomics</i> , 2015, 11, 620-635.	3.0	17
31	Mass Spectrometry-Based Identification of Muscle-Associated and Muscle-Derived Proteomic Biomarkers of Dystrophinopathies. <i>Journal of Neuromuscular Diseases</i> , 2014, 1, 15-40.	2.6	15
32	Identification of marker proteins of muscular dystrophy in the urine proteome from the mdx-4cv model of dystrophinopathy. <i>Molecular Omics</i> , 2020, 16, 268-278.	2.8	14
33	Mass Spectrometric Profiling of Extraocular Muscle and Proteomic Adaptations in the mdx-4cv Model of Duchenne Muscular Dystrophy. <i>Life</i> , 2021, 11, 595.	2.4	14
34	Histopathology of Duchenne muscular dystrophy in correlation with changes in proteomic biomarkers. <i>Histology and Histopathology</i> , 2021, , 18403.	0.7	14
35	Quantitative label-free mass spectrometry analysis of formalin-fixed, paraffin-embedded tissue representing the invasive cutaneous malignant melanoma proteome. <i>Oncology Letters</i> , 2016, 12, 3296-3304.	1.8	13
36	Proteomic profiling of giant skeletal muscle proteins. <i>Expert Review of Proteomics</i> , 2019, 16, 241-256.	3.0	13

#	ARTICLE	IF	CITATIONS
37	Intricate effects of primary motor neuronopathy on contractile proteins and metabolic muscle enzymes as revealed by label-free mass spectrometry. <i>Bioscience Reports</i> , 2014, 34, .	2.4	12
38	<i>N</i>-Linked glycosylation profiles of therapeutic induced senescent (TIS) triple negative breast cancer cells (TNBC) and their extracellular vesicle (EV) progeny. <i>Molecular Omics</i> , 2021, 17, 72-85.	2.8	12
39	Proteomic profiling of fatty acid binding proteins in muscular dystrophy. <i>Expert Review of Proteomics</i> , 2020, 17, 137-148.	3.0	11
40	Proteomic profiling of carbonic anhydrase CA3 in skeletal muscle. <i>Expert Review of Proteomics</i> , 2021, 18, 1073-1086.	3.0	11
41	Saliva-omics in plasma cell disorders- Proof of concept and potential as a non-invasive tool for monitoring disease burden. <i>Journal of Proteomics</i> , 2021, 231, 104015.	2.4	9
42	New pathobiochemical insights into dystrophinopathy from the proteomics of senescent mdx mouse muscle. <i>Frontiers in Aging Neuroscience</i> , 2014, 6, 109.	3.4	8
43	Next generation proteomics with drug sensitivity screening identifies sub-clones informing therapeutic and drug development strategies for multiple myeloma patients. <i>Scientific Reports</i> , 2021, 11, 12866.	3.3	8
44	Proteomic profiling of the interface between the stomach wall and the pancreas in dystrophinopathy. <i>European Journal of Translational Myology</i> , 2021, 31, .	1.7	7
45	DIGE Analysis of ProteoMiner™ Fractionated Serum/Plasma Samples. <i>Methods in Molecular Biology</i> , 2018, 1664, 109-114.	0.9	6
46	Clinical Proteomics of Biofluids in Haematological Malignancies. <i>International Journal of Molecular Sciences</i> , 2021, 22, 8021.	4.1	6
47	Identification of Protein Biomarker Signatures for Acute Myeloid Leukemia (AML) Using Both Nontargeted and Targeted Approaches. <i>Proteomes</i> , 2021, 9, 42.	3.5	6
48	DIGE Analysis of Immunodepleted Plasma. <i>Methods in Molecular Biology</i> , 2018, 1664, 245-257.	0.9	5
49	S100 Calcium Binding Protein Family Members Associate With Poor Patient Outcome and Response to Proteasome Inhibition in Multiple Myeloma. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 723016.	3.7	5
50	DIGE Analysis Software and Protein Identification Approaches. <i>Methods in Molecular Biology</i> , 2018, 1664, 41-50.	0.9	3
51	Dataset on the mass spectrometry-based proteomic profiling of the kidney from wild type and the dystrophic mdx-4cv mouse model of X-linked muscular dystrophy. <i>Data in Brief</i> , 2020, 28, 105067.	1.0	3
52	Phase 2 studies of lenalidomide, subcutaneous bortezomib, and dexamethasone as induction therapy in patients with newly diagnosed multiple myeloma. <i>American Journal of Hematology</i> , 2022, 97, 562-573.	4.1	3
53	DIGE Saturation Labeling for Scarce Amounts of Protein from Formalin-Fixed Paraffin-Embedded (FFPE) Tissue. <i>Methods in Molecular Biology</i> , 2018, 1664, 87-91.	0.9	1
54	Examining the Impact of Altered Protein Expression and Ubiquitination Levels on the Development of Resistance to Proteasome Inhibitors Using Proteomics Analysis. <i>Blood</i> , 2015, 126, 4208-4208.	1.4	0